XPC and ovarian carcinoma: Particularly for XPC, lessons learned from other tumors such as ovarian carcinoma suggest that the XPC poly (AT) (PAT) (−/+)/ (−/−) genotype versus the (+/+) genotype is associated with a prolonged progression-free survival after treatment with platinum-based chemotherapy (17 months versus 11.6 months) [19].